|
1
|
Sherman M: Hepatocellular carcinoma:
epidemiology, surveillance, and diagnosis. Semin Liver Dis.
30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kirk GD, Lesi OA, Mendy M, et al: The
Gambia Liver Cancer Study: Infection with hepatitis B and C and the
risk of hepatocellular carcinoma in West Africa. Hepatology.
39:211–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Benowitz S: Liver cancer biomarkers
struggling to succeed. J Natl Cancer Inst. 99:590–591. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jie L, Fan W, Weiqi D, et al: The
hippo-yes association protein pathway in liver cancer.
Gastroenterol Res Pract. 2013:1870702013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang F, He L, Dai W, et al: Salinomycin
inhibits proliferation and induces apoptosis of human
hepatocellular carcinoma cells in vitro and in vivo. PLoS One.
7:e506382012. View Article : Google Scholar
|
|
7
|
Dai W, Wang F, He L, et al: Genistein
inhibits hepatocellular carcinoma cell migration by reversing the
epithelial-mesenchymal transition: Partial mediation by the
transcription factor NFAT1. Mol Carcinog. Nov 14–2013.(Epub ahead
of print). View
Article : Google Scholar
|
|
8
|
Wu D, Wang F, Dai W, et al: The miR-146a
rs 2910164 G > C polymorphism increases the susceptibility to
digestive cancer in Chinese. Asian Pacific J Cancer Prev.
14:399–403. 2013. View Article : Google Scholar
|
|
9
|
Sherlock S: Viruses and hepatocellular
carcinoma. Gut. 35:828–832. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou Y, Yin X, Ying J and Zhang B: Golgi
protein 73 versus alpha-fetoprotein as a biomarker for
hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer.
12:172012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zoli M, Magalotti D, Bianchi G, et al:
Efficacy of a surveillance program for early detection of
hepatocellular carcinoma. Cancer. 78:977–985. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
el-Serag HB: Global epidemiology of
hepatocellular carcinoma. Clin Liver Dis. 5:87–107. 2001.
View Article : Google Scholar
|
|
13
|
Block TM, Comunale MA, Lowman M, et al:
Use of targeted glycoproteomics to identify serum glycoproteins
that correlate with liver cancer in woodchucks and humans. Proc
Natl Acad Sci USA. 102:779–784. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schwegler EE, Cazares L, Steel LF, et al:
SELDI-TOF MS profiling of serum for detection of the progression of
chronic hepatitis C to hepatocellular carcinoma. Hepatology.
41:634–642. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iftikhar R, Kladney RD, Havlioglu N, et
al: Disease- and cell-specific expression of GP73 in human liver
disease. Am J Gastroenterol. 99:1087–1095. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maitra A and Thuluvgth PJ: GP73 and liver
disease: a (Golgi)complex enigma. Am J Gastroenterol. 99:1096–1098.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bruix J, Sherman M, Llovet JM, et al: EASL
Panel of Experts on HCC: Clinical management of hepatocellular
carcinoma. Conclusions of the Barcelona-2000 EASL conference
European Association for the Study of the Liver. J Hepatol.
35:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu D, Wu SM, Lu J, et al: Rifaximin versus
nonabsorbable disaccharides for the treatment of hepatic
encephalopathy: a meta-analysis. Gastroenterol Res Pract.
2013:2369632013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Lu J, Dai W, et al: Combination
therapy of ursodeoxycholic acid and corticosteroids for primary
biliary cirrhosis with features of autoimmune hepatitis: a
meta-analysis. Gastroenterol Res Pract. 2013:4907312013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Whiting P, Rutjes AWS, Reitsma JB, et al:
The development of QUADAS: a tool for the quality assessment of
studies of diagnostic accuracy included in systematic reviews. BMC
Medical Res Methodol. 3:252003. View Article : Google Scholar
|
|
21
|
Özkan H, Erdal H, Tutkak H, et al:
Diagnostic and prognostic validity of Golgi protein 73 in
hepatocellular carcinoma. Digestion. 83:83–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu JS, Wu DW, Liang S and Miao XY: GP73, a
resident Golgi glycoprotein, is sensibility and specificity for
hepatocellular carcinoma of diagnosis in a hepatitis B-endemic
Asian population. Med Oncol. 27:339–345. 2010. View Article : Google Scholar
|
|
23
|
Mao Y, Yang H, Xu H, et al: Golgi protein
73 (GOLPH2) is a valuable serum marker for hepatocellular
carcinoma. Gut. 59:1687–1693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marrero JA, Romano PR, Nikolaeva O, et al:
GP73, a resident Golgi glycoprotein, is a novel serum marker for
hepatocellular carcinoma. J Hepatol. 43:1007–1012. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morota K, Nakagawa M, Sekiya R, et al: A
comparative evaluation of Golgi protein-73, fucosylated hemopexin,
α-fetoprotein, and PIVKA-II in the serum of patients with chronic
hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab
Med. 49:711–718. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi Y, Chen J, Li L, et al: A study of
diagnostic value of golgi protein GP73 and its genetic assay in
primary hepatic carcinoma. Technol Cancer Res Treat. 10:287–294.
2011.PubMed/NCBI
|
|
27
|
Tian L, Wang Y, Xu D, et al: Serological
AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic
diseases. Int J Cancer. 129:1923–1931. 2011. View Article : Google Scholar
|
|
28
|
Wang M, Long RE, Comunale MA, et al: Novel
fucosylated biomarkers for the early detection of hepatocellular
carcinoma. Cancer Epidemiol Biomarkers Prev. 18:1914–1921. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu WF, Fei YM, Zhou JK, et al:
Significance of serum golgi protein 73 (GP73), alpha-fetoprotein
(AFP) and lectin-reactive alpha-fetoprotein (AFP-L3) expresssion in
primary hepatic carcinoma. Zhonghua Shi Yan He Lin Chuang Bing Du
Xue Za Zhi. 25:286–288. 2011.(In Chinese). PubMed/NCBI
|
|
30
|
Zhao XY, Li N, Ding HG and Jiang FF:
Detection and evaluation of serum GP73, a resident Golgi
glycoprotein, as a marker in diagnosis of hepatocellular carcinoma.
Zhonghua Zhong Liu Za Zhi. 32:943–945. 2010.(In Chinese).
|
|
31
|
Wang Y, Yang H, Xu H, et al: Golgi protein
73, not Glypican-3, may be a tumor marker complementary to
α-Fetoprotein for hepatocellular carcinoma diagnosis. J
Gastroenterol Hepatol. 29:597–602. 2014. View Article : Google Scholar
|
|
32
|
Hou SC, Xiao MB, Ni RZ, et al: Serum GP73
is complementary to AFP and GGT-II for the diagnosis of
hepatocellular carcinoma. Oncol Lett. 6:1152–1158. 2013.PubMed/NCBI
|
|
33
|
Whiting P, Harbord R and Kleijnen J: No
role for quality scores in systematic reviews of diagnostic
accuracy studies. BMC Med Res Methodol. 5:192005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deeks JJ: Systematic reviews in health
care: Systematic reviews of evaluations of diagnostic and screening
tests. BMJ. 323:157–162. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Walter SD: Properties of the summary
receiver operating characteristic (SROC) curve for diagnostic test
data. Stat Med. 21:1237–1256. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Leeflang MM, Deeks JJ, Gatsonis C and
Bossuyt PM; Cochrane Diagnostic Test Accuracy Working Group.
Systematic reviews of diagnostic test accuracy. Ann Intern Med.
149:889–897. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deeks JJ, Macaskill P and Irwig L: The
performance of tests of publication bias and other sample size
effects in systematic reviews of diagnostic test accuracy was
assessed. J Clin Epidemiol. 58:882–893. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Song F, Khan KS, Dinnes J and Sutton AJ:
Asymmetric funnel plots and publication bias in meta-analyses of
diagnostic accuracy. Int J Epidemiol. 31:88–95. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kladney RD, Bulla GA, Guo L, et al: GP73,
a novel Golgi-localized protein upregulated by viral infection.
Gene. 249:53–65. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Puri S, Bachert C, Fimmel CJ and Linstedt
AD: Cycling of early Golgi proteins via the cell surface and
endosomes upon lumenal pH disruption. Traffic. 3:641–653. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Comunale MA, Mattu TS, Lowman MA, et al:
Comparative proteomic analysis of de-N-glycosylated serum from
hepatitis B carriers reveals polypeptides that correlate with
disease status. Proteomics. 4:826–838. 2004. View Article : Google Scholar : PubMed/NCBI
|
